Ameriprise Financial Inc. Buys 18,730 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Ameriprise Financial Inc. boosted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 22.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 103,801 shares of the company's stock after purchasing an additional 18,730 shares during the period. Ameriprise Financial Inc. owned about 0.18% of Harmony Biosciences worth $3,572,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of HRMY. Barclays PLC lifted its position in Harmony Biosciences by 110.9% during the third quarter. Barclays PLC now owns 76,862 shares of the company's stock valued at $3,074,000 after purchasing an additional 40,416 shares in the last quarter. SG Americas Securities LLC lifted its position in Harmony Biosciences by 43.1% during the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the company's stock valued at $774,000 after purchasing an additional 6,774 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in Harmony Biosciences by 9.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 17,445 shares of the company's stock valued at $600,000 after purchasing an additional 1,550 shares in the last quarter. KBC Group NV lifted its position in Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after purchasing an additional 819 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its position in Harmony Biosciences by 18.2% during the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after purchasing an additional 351,582 shares in the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Harmony Biosciences Price Performance

Shares of HRMY stock traded up $0.33 during trading hours on Friday, hitting $34.38. The stock had a trading volume of 531,767 shares, compared to its average volume of 608,730. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock's 50-day moving average price is $31.54 and its two-hundred day moving average price is $33.98. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 16.29, a PEG ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $184.73 million for the quarter, compared to analysts' expectations of $184.26 million. During the same period in the previous year, the firm posted $0.67 earnings per share. The business's revenue was up 19.5% compared to the same quarter last year. Equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HRMY. Mizuho lifted their target price on Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a research report on Thursday, May 15th. Needham & Company LLC restated a "buy" rating and issued a $49.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, May 6th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, April 8th. UBS Group lowered their price objective on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Finally, Cantor Fitzgerald upgraded Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Harmony Biosciences has a consensus rating of "Buy" and a consensus target price of $52.78.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.